Natera, Inc. has announced the appointment of Steve Chapman as Chief Executive Officer (CEO) with effect from January 2, 2019 and Robert Schueren as Chief Operating Officer (COO) effective January 7, 2019. Previously, Chapman was the company's COO and will succeed Matthew Rabinowitz, Ph.D., Natera co-founder and CEO. Rabinowitz will remain integrally involved as Executive Chairman focusing on the company's long-term business strategy and technology innovation.

Chapman is a proven strategic business leader with deep, hands-on experience in the field of genetic diagnostic testing and has repeatedly delivered winning growth strategies, leveraging extensive commercialization and reimbursement expertise. Since joining Natera in 2010, Chapman has delivered extraordinary results in roles ranging from Vice President of Sales, to Senior Vice President of Commercial, to Chief Commercial Officer and most recently COO. Chapman was previously at Genzyme Genetics, where he was credited with delivering record-breaking commercial growth and strategies that changed pregnancy genetic testing.

Schueren is an accomplished industry veteran with extensive molecular diagnostics and genomics experience, having served in executive leadership roles at companies including IntegenX Inc. (recently acquired by Thermo Fisher Scientific), Agilent Technologies, and Genentech. On January 1, 2019, Matthew Rabinowitz resigned as Chief Executive Officer and President, effective as of the start of business on January 2, 2019.